Phage-display and competitive panning elution leads to the identification of minimum-sized antigen binders together with conventional antibodies from a mouse cDNA library constructed from HM-1 killer toxin neutralizing monoclonal antibody (nmAb-KT). Antigen-specific altered camelid-like single-domain heavy chain antibody (scFv K2) and a conventional antibody (scFv K1) have been isolated against the idiotypic antigen nmAb-KT. The objectives of the study were to examine (1) their properties as compared to conventional antibodies and also (2) their antifungal activity against different pathogenic and non-pathogenic fungal species. The alternative small antigen-binder, i.e., the single-domain heavy chain antibody, was originated from a conventional mouse scFv phage library through somatic hyper-mutation while selection against antigen. This single-domain antibody fragment was well expressed in bacteria and specifically bound with the idiotypic antigen nmAb-KT and had a high stability and solubility. Experimental data showed that the binding affinity for this single-domain antibody was 272-fold higher (K d = 1.07 × 10−10 M) and antifungal activity was three- to fivefold more efficient (IC50 = 0.46 × 10−6 to 1.17 × 10−6 M) than that for the conventional antibody (K d = 2.91 × 10−8 M and IC50 = 2.14 × 10−6 to 3.78 × 10−6 M). The derived single-domain antibody might be an ideal scaffold for anti-idiotypic antibody therapy and the development of smaller peptides or peptide mimetic drugs due to their less complex antigen-binding site. We expect that such single-domain synthetic antibodies will find their way into a number of biotechnological or medical applications.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Bird RE, Hardman KD, Jacobson JW, Johnson S, Kaufman BM, Lee SM, Lee T, Pope SH, Riordan GS, Whitlow M (1988) Single-chain antigen-binding proteins. Science 242:423–426
Cassone A (2008) Fungal vaccines: real progress from real challenges. Lancet Infect Dis 2:114–124
Cutler JE, Deepe GS Jr, Klein BS (2007) Advances in combating fungal diseases: vaccines on the threshold. Nat Rev Microbiol 1:13–28
de Haard HJ, van Neer N, Reurs A, Hufton SE, Roovers RC, Henderikx P, de Bruïne AP, Arends JW, Hoogenboom HR (1999) A large non-immunized human Fab fragment phage library that permits rapid isolation and kinetic analysis of high affinity antibodies. J Biol Chem 274:18218–18230
Dumoulin M, Conrath K, Van Meirhaeghe A, Meersman F, Heremans K, Frenken LG, Muyldermans S, Wyns L, Matagne A (2002) Single-domain antibody fragments with high conformational stability. Protein Sci 11:500–515
Ghahroudi MA, Desmyter A, Wyns L, Hamers R, Muyldermans S (1997) Selection and identification of single domain antibody fragments from camel heavy-chain antibodies. FEBS Lett 414:521–526
Griffiths AD, Williams SC, Hartley O, Tomlinson IM, Waterhouse P, Crosby WL, Kontermann RE, Jones PT, Low NM, Allison TJ, Prospero TD, Hoogenboom HR, Nissim A, Cox JPL, Harrison JL, Zaccolo M, Gherardi E, Winter G (1994) Isolation of high affinity human antibodies directly from large synthetic repertoires. EMBO J 13:3245–3260
Gruen LC, Kortt AA, Nice E (1993) Determination of relative binding affinity of influenza virus N9 sialidases with the Fab fragment of monoclonal antibody NC41 using biosensor technology. Eur J Biochem 217:319–325
Hamers-Casterman C, Atarhouch T, Muyldermans S, Robinson G, Hamers C, Songa EB, Bendahman N, Hamers R (1993) Naturally occurring antibodies devoid of light chains. Nature 363:446–448
Harmsen MM, De Haard HJ (2007) Properties, production, and applications of camelid single domain antibody fragments. Appl Microbiol Biotechnol 77:13–22
Holliger P, Prospero T, Winter G (1993) “Diabodies”: small bivalent and bispecific antibody fragments. Proc Natl Acad Sci USA 90:6444–6448
Hoogenboom HR (2002) Overview of antibody phage-display technology and its applications. Methods Mol Biol 178:1–37
Huston JS, Levinson D, Mudgett-Hunter M, Tai MS, Novotný J, Margolies MN, Ridge RJ, Bruccoleri RE, Haber E, Crea R, Oppermann H (1988) Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli. Proc Natl Acad Sci USA 85:5879–5883
Kabat EA, Wu TT (1991) Identical V region amino acid sequences and segments of sequences in antibodies of different specificities. Relative contributions of VH and VL genes, minigenes, and complementarity-determining regions to binding of antibody-combining sites. J Immunol 147:1709–1719
Kabat EA, Wu TT, Perry H, Gottesman K, Foeller C (1991) Sequences of proteins of immunological interest, 5th edn. National Institutes of Health, Bethesda
Kabir ME, Krishnaswamy S, Miyamoto M, Furuichi Y, Komiyama T (2009) An improved phage-display panning method to produce an HM-1 killer toxin anti-idotypic antibody. BMC Biotechnol 9:99
Kabir ME, Krishnaswamy S, Miyamoto M, Furuichi Y, Komiyama T (2010) Purification and functional characterization of a camelid-like single-domain antimycotic antibody by engineering in affinity tag. Protein Expr Purif 72:59–65
Kasahara S, Ben Inoue S, Mio T, Yamada T, Nakajima T, Ichishima E, Furuichi Y, Yamada H (1994) Involvement of cell wall beta-glucan in the action of HM-1 killer toxin. FEBS Lett 1:27–32
Komiyama T, Ohta T, Urakami H, Shiratori Y, Takasuka T, Satoh M, Watanabe T, Furuichi Y (1996) Pore formation on proliferating yeast Saccharomyces cerevisiae cell buds by HM-1 killer toxin. J Biochem 4:731–736
Komiyama T, Shirai T, Ohta T, Urakami H, Furuichi Y, Ohta Y, Tsukada Y (1998) Action properties of HYI killer toxin from Williopsis saturnus var. saturnus, and antibiotics, aculeacin A and papulacandin B. Biol Pharm Bull 10:1013–1019
Lendvai N, Qu XW, Hsueh W, Casadevall A (2000) Mechanism for the isotype dependence of antibody-mediated toxicity in Cryptococcus neoformans-infected mice. J Immunol 164:4367–4374
Levitz SM (1991) The ecology of Cryptococcus neoformans and the epidemiology of cryptococcosis. Rev Infect Dis 13:1163–1169
Lu D, Shen J, Vil MD, Zhang H, Jimenez X, Bohlen P, Whitte L, Zhu Z (2003) Tailoring in vitro selection for a picomolar affinity human antibody directed against vascular endothelial growth factor receptor 2 for enhanced neutralizing activity. J Biol Chem 278:43496–43507
Majidi J, Barar J, Baradaran B, Abdolalizadeh J, Omidi Y (2009) Target therapy of cancer: implementation of monoclonal antibodies and nanobodies. Hum Antibodies 18:81–100
Mitchell TG, Perfect JR (1995) Cryptococcosis in the era of AIDS: 100 years after the discovery of Cryptococcus neoformans. Clin Microbiol Rev 8:515–548
Muyldermans S, Atarhouch T, Saldanha J, Barbosa JA, Hamers R (1994) Sequence and structure of VH domain from naturally occurring camel heavy chain immunoglobulins lacking light chains. Protein Eng 7:1129–1135
Pfaller MA, Diekema DJ (2007) Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 20:133–163
Rahbarizadeh F, Rasaee MJ, Forouzandeh-Moghadam M, Allameh AA (2005) High expression and purification of the recombinant camelid anti-MUC1 single domain antibodies in Escherichia coli. Protein Expr Purif 44:32–38
Selvakumar D, Miyamoto M, Furuichi Y, Komiyama T (2006) Inhibition of fungal β-1,3-glucan synthase and cell growth by HM-1 killer toxin single-chain anti-idiotypic antibodies. Antimicrob Agents Chemother 50:3090–3097
Shoham S, Levitz SM (2005) The immune response to fungal infections. Br J Haematol 129:569–582
Singh N, Gayowski T, Wagener MM, Marino IR (1997) Clinical spectrum of invasive cryptococcosis in liver transplant recipients receiving tacrolimus. Clin Transplant 11:66–70
Takasuka T, Komiyama T, Furuichi Y, Watanabe T (1995) Cell wall synthesis specific cytocidal effect of Hansenula mrakii toxin-1 on Saccharomyces cerevisiae. Cell Mol Biol Res 41:575–581
Van Bockstaele F, Holz JB, Revets H (2009) The development of nanobodies for therapeutic applications. Curr Opin Investig Drugs 10:1212–1224
Vaughan TJ, Williams AJ, Pritchard K, Osbourn JK, Pope AR, Earnshaw JC, McCafferty J, Hodits RA, Wilton J, Johnson KS (1996) Human antibodies with sub-nanomolar affinities isolated from a large non-immunized phage display library. Nat Biotechnol 14:309–314
Ward ES, Güssow D, Griffiths AD, Jones PT, Winter G (1989) Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli. Nature 341:544–546
Yamamoto T, Imai M, Tachibana K, Mayumi M (1986) Application of monoclonal antibodies to the isolation and characterization of a killer toxin secreted by Hansenula mrakii. FEBS Lett 195:253–257
Yamamoto T, Uchida K, Hiratani T, Miyazaki T, Yagiu J, Yamaguchi H (1988) In vitro activity of the killer toxin from yeast Hansenula mrakii against yeasts and molds. J Antibiot (Tokyo) 41:398–403
Yau KYF, Tout NL, Trevors JT, Lee H, Hall JC (1998) Bacterial expression and characterization of a picloram-specific recombinant Fab for residue analysis. J Agric Food Chem 46:4457–4463
This research work was supported by a grant from the Ministry of Education, Culture, Sports, Science, and Technology of Japan. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
M.E. Kabir and T. Komiyama conceived and designed the experiments. M.E. Kabir and S. Krishnaswamy performed the experiments. M.E. Kabir, M. Miyamoto, Y. Furuichi, and T. Komiyama analyzed the data. M.E. Kabir wrote the paper.
About this article
Cite this article
Kabir, M.E., Krishnaswamy, S., Miyamoto, M. et al. An altered camelid-like single domain anti-idiotypic antibody fragment of HM-1 killer toxin: acts as an effective antifungal agent. Appl Microbiol Biotechnol 90, 553–564 (2011). https://doi.org/10.1007/s00253-011-3123-8
- Phage-display panning
- Single-domain antibody fragment
- Antifungal activity
- HM-1 killer toxin
- Killer toxin (HM-1) neutralizing monoclonal antibody